152 related articles for article (PubMed ID: 32104311)
1. Mixed PEGylated surfactant modifying system decrease the accelerated blood clearance phenomenon of nanoemulsions in rats.
Su Y; Tang W; Song Y; Wang C; Tian Q; Wang X; Quan J; Li B; Wang S; Deng Y
Asian J Pharm Sci; 2017 Jan; 12(1):28-36. PubMed ID: 32104311
[TBL] [Abstract][Full Text] [Related]
2. Accelerated Blood Clearance of Nanoemulsions Modified with PEG-Cholesterol and PEG-Phospholipid Derivatives in Rats: The Effect of PEG-Lipid Linkages and PEG Molecular Weights.
Liu M; Chu Y; Liu H; Su Y; Zhang Q; Jiao J; Liu M; Ding J; Liu M; Hu Y; Dai Y; Zhang R; Liu X; Deng Y; Song Y
Mol Pharm; 2020 Apr; 17(4):1059-1070. PubMed ID: 31860321
[TBL] [Abstract][Full Text] [Related]
3. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
4. PEGylated nanoemulsions containing 1,2-distearoyl-sn-glycero-3-phosphoglycerol induced weakened accelerated blood clearance phenomenon.
Li Z; Gao X; Yan X; Deng Y; Ma H
Drug Deliv Transl Res; 2022 Oct; 12(10):2569-2579. PubMed ID: 35094294
[TBL] [Abstract][Full Text] [Related]
5. Effects of Uncleavable and Cleavable PEG-Lipids with Different Molecular Weights on Accelerated Blood Clearance of PEGylated Emulsions in Beagle Dogs.
Jiao J; Luo X; Wang C; Jiao X; Liu M; Liu X; Wei L; Deng Y; Song Y
AAPS PharmSciTech; 2020 Mar; 21(3):106. PubMed ID: 32185548
[TBL] [Abstract][Full Text] [Related]
6. Optimization of PEGylated nanoemulsions for improved pharmacokinetics of BCS class II compounds.
Devalapally H; Zhou F; McDade J; Goloverda G; Owen A; Hidalgo IJ; Silchenko S
Drug Deliv; 2015; 22(4):467-74. PubMed ID: 24344786
[TBL] [Abstract][Full Text] [Related]
7. The accelerated blood clearance phenomenon of PEGylated nanoemulsion upon cross administration with nanoemulsions modified with polyglycerin.
Su Y; Wang L; Liang K; Liu M; Liu X; Song Y; Deng Y
Asian J Pharm Sci; 2018 Jan; 13(1):44-53. PubMed ID: 32104377
[TBL] [Abstract][Full Text] [Related]
8. Evasion of the accelerated blood clearance phenomenon by branched PEG lipid derivative coating of nanoemulsions.
Liu M; Zhao D; Yan N; Li J; Zhang H; Liu M; Tang X; Liu X; Deng Y; Song Y; Zhao X
Int J Pharm; 2022 Jan; 612():121365. PubMed ID: 34896215
[TBL] [Abstract][Full Text] [Related]
9. Branched PEG-modification: A new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy.
Liu M; Li J; Zhao D; Yan N; Zhang H; Liu M; Tang X; Hu Y; Ding J; Zhang N; Liu X; Deng Y; Song Y; Zhao X
Biomaterials; 2022 Apr; 283():121415. PubMed ID: 35217484
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Accelerated Blood Clearance Phenomenon of PEGylated Nanoemulsions in Rats by Intraperitoneal Administration.
Su Y; Liu M; Liang K; Liu X; Song Y; Deng Y
AAPS PharmSciTech; 2018 Oct; 19(7):3210-3218. PubMed ID: 30187444
[TBL] [Abstract][Full Text] [Related]
11. Using Bio-Layer Interferometry to Evaluate Anti-PEG Antibody-Mediated Complement Activation.
Mostafa M; Elsadek NE; Emam SE; Ando H; Shimizu T; Abdelkader H; Ishima Y; Aly UF; Sarhan HA; Ishida T
Biol Pharm Bull; 2022; 45(1):129-135. PubMed ID: 34980774
[TBL] [Abstract][Full Text] [Related]
12. Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers.
Ishihara T; Maeda T; Sakamoto H; Takasaki N; Shigyo M; Ishida T; Kiwada H; Mizushima Y; Mizushima T
Biomacromolecules; 2010 Oct; 11(10):2700-6. PubMed ID: 20795699
[TBL] [Abstract][Full Text] [Related]
13. Comparison among different "revealers" in the study of accelerated blood clearance phenomenon.
Liang K; Wang L; Su Y; Liu M; Feng R; Song Y; Deng Y
Eur J Pharm Sci; 2018 Mar; 114():210-216. PubMed ID: 29247685
[TBL] [Abstract][Full Text] [Related]
14. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
15. Time Interval of Two Injections and First-Dose Dependent of Accelerated Blood Clearance Phenomenon Induced by PEGylated Liposomal Gambogenic Acid: The Contribution of PEG-Specific IgM.
Wang F; Ye X; Wu Y; Wang H; Sheng C; Peng D; Chen W
J Pharm Sci; 2019 Jan; 108(1):641-651. PubMed ID: 30595169
[TBL] [Abstract][Full Text] [Related]
16. Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery.
Abu Lila AS; Uehara Y; Ishida T; Kiwada H
J Pharm Sci; 2014 Feb; 103(2):557-66. PubMed ID: 24347396
[TBL] [Abstract][Full Text] [Related]
17. Effect of PEG surface conformation on anticancer activity and blood circulation of nanoemulsions loaded with tocotrienol-rich fraction of palm oil.
Alayoubi A; Alqahtani S; Kaddoumi A; Nazzal S
AAPS J; 2013 Oct; 15(4):1168-79. PubMed ID: 23990503
[TBL] [Abstract][Full Text] [Related]
18. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage.
Abu Lila AS; Kiwada H; Ishida T
J Control Release; 2013 Nov; 172(1):38-47. PubMed ID: 23933235
[TBL] [Abstract][Full Text] [Related]
19. Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice.
Taguchi K; Urata Y; Anraku M; Watanabe H; Kadowaki D; Sakai H; Horinouchi H; Kobayashi K; Tsuchida E; Maruyama T; Otagiri M
Drug Metab Dispos; 2009 Nov; 37(11):2197-203. PubMed ID: 19679674
[TBL] [Abstract][Full Text] [Related]
20. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
